Heart failure (HF) is a clinical syndrome with a global burden. Signs and symptoms of HF are non-specific and often shared with other conditions. NT-proBNP serves as a useful biomarker for the diagnosis of HF not only in patients with acute symptoms but also in outpatients with an ambiguous clinical presentation. The aim of the analysis is to evaluate the cost-effectiveness of implementing NT-proBNP in the diagnostic algorithm in patients with/without type-2-diabetes-mellitus (T2DM), compared to a diagnosis based primarily on clinical signs or symptoms from the perspective of the Austrian and Swiss health-care-system.